Corrigendum to "Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study" [Schizophrenia Research 93 (1-3) (2007) 117-130] (DOI:10.1016/j.schres.2007.03.003);Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study

Schizophrenia Research

Volumn 93, Issue 1-3, 2007, Pages 117-130

  Davidson, Michael ^a   Emsley, Robin ^b   Kramer, Michelle ^c   Ford, Lisa ^c   Pan, Guohua ^c   Lim, Pilar ^c   Eerdekens, Mariëlle ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Atypical antipsychotic; Efficacy; Paliperidone ER; Schizophrenia; Tolerability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BIPERIDEN; OLANZAPINE; PALIPERIDONE; PROLACTIN;

ADULT; AGITATION; AKATHISIA; ANORGASMIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECG ABNORMALITY; EXTENDED RELEASE FORMULATION; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HEART BUNDLE BRANCH BLOCK; HUMAN; HYPERKINESIA; IMPOTENCE; INSOMNIA; LACTATION DISORDER; LACTATION NONPUERPUERAL; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE HYPERTONIA; NAUSEA; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOCIAL INTERACTION; SOMNOLENCE; SYMPTOM; TABLET FORMULATION; TACHYCARDIA; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 34249275309     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.07.014     Document Type: Erratum

References (31)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 60 12 (2003) 1228-1235
2. Agid O., Seeman P., and Kapur S. The "delayed onset" of antipsychotic action-an idea whose time has come and gone. J. Psychiatry Neurosci. 31 2 (2006) 93-100
3. Bhana N., Foster R.H., Olney R., and Plosker G.L. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61 1 (2001) 111-161
4. Cleton A., Talluri K., Leempoels A., Thyssen A., Janssens L., Eerdekens M., and Boom S. No pharmacokinetic interaction between trimethoprim and paliperidone ER in healthy subjects. Clin. Pharmacol. Ther. 79 2 (2006) 22 (Abstract)
5. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., and Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 160 11 (2003) 2063-2065
6. Emsley R., Rabinowitz J., and Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am. J. Psychiatry 163 4 (2006) 743-745
7. Ereshefsky L., and Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry 64 Suppl 16 (2003) 18-23
8. Gagnon D.D., Nasrallah H., and Morosini P.-L. Reliability, validity and sensitivity to change of the Personal and Social Performance Scale in patients with stable schizophrenia. Int. J. Neuropsychopharmacol. 9 Suppl 1 (2006) S288 (Abstract)
9. Guy W. ECDEU Assessment of Manual for Psychopharmacology, revised. U.S. Department of Health (1976), Education and Welfare publication (ADM) 76-338
10. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?. Acta Psychiatr. Scand. 81 3 (1990) 231-235
11. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., and Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63 10 (2006) 1079-1087
12. Kane J., Canas F., Kramer M., Ford L., Gassman-Mayer C., Lim P., and Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Biol. Psychiatry 90 (2007) 147-161
13. Karlsson P., Dencker E., Nyberg S., Mannaert E., Boom S., Talluri K., Rossenu S., Eriksson B., Eerdekens M., and Farde L. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur. Neuropsychopharmacol. 15 Suppl 3 (2005) S385 (Abstract)
14. Kay S., Opler L., and Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual (1986), Multi-Health System, North Tohawanda, NY
15. Kramer M., Kushner S., Vijapurkar U., Lim P., and Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 27 1 (2007) 6-14
16. Lambert M., and Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS. Drugs 18 Suppl 2 (2004) 5-17 (discussion 41-13)
17. Lehman A.F. Vocational rehabilitation in schizophrenia. Schizophr. Bull. 21 4 (1995) 645-656
18. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 57 12 (2005) 1543-1549
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
20. Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 58 12 (1997) 538-546
21. Marder, S., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., Lowy, A., in press. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo controlled study. Biol. Psychiatry.
22. May P., Van Putten T., and Yale C. Predicting outcome of antipstychotic drug treatment from early response. Am. J. Psychiatry 137 (1980) 1088-1089
23. Morosini P.-L., Magliano L., Brambilla L., Ugolini S., and Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 101 4 (2000) 323-329
24. Nasrallah H.A., Targum S.D., Tandon R., McCombs J.S., and Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr. Serv. 56 3 (2005) 273-282
25. Patrick D., Morosini P.-L., and Rothman M. Reliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophrenia. Int. J. Neuropsychopharmacol. 9 Suppl 1 (2006) S287-S288 (Abstract)
26. Peuskens J., and Group R.S. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br. J. Psychiatry 166 (1995) 712-716
27. Rossenu S., Cleton A., Talluri K., Francetic I., Remmerie B., Janssen L., Eerdekens M., and Boom C. Comparison of pharmacodynamic parameters resulting from administration of paliperidone extended-release tablet formulation and an immediate-release formulation of risperidone in subjects with schizophrenia. Clin. Pharmacol. Ther. 81 Suppl 1 (2007) S62 (Abstract)
28. Spina E., and Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43 Suppl 2 (2002) 37-44
29. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., and Hsiao J.K. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 4 (2006) 611-622
30. Vermeir M., Boom S., Naessens I., Talluri K., and Eerdekens M. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur. Neuropsychopharmacol. 15 Suppl 3 (2005) S648 (Abstract)
31. Wyatt R. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17 (1991) 325-351